Arrow
Arrow
Slider

Premaitha Health PLC
(“Premaitha” or the “Company” or the “Group”)

Completion of Yourgene Acquisition, Issue of Shares and Director Appointments

Manchester, UK – 27 February 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, announces regulatory clearance for the completion of the acquisition of Yourgene Bioscience Co., Ltd (“Yourgene”).

The acquisition of Yourgene, announced on 21 December 2016, has now received regulatory clearance as required by Taiwanese law.  Legal completion of the acquisition is expected to take place on 2 March 2017, upon admission to AIM of 76,054,570 new ordinary shares in the Company (the “Acquisition Shares”).  Once the Acquisition Shares have been admitted, the Company will have in issue 321,218,279 ordinary shares of 0.1 pence.

Upon completion of the acquisition, Dr Bill Chang and Mr Alan Chang will be appointed as Directors of the Company.

Yourgene is a significant Asian non-invasive prenatal testing (“NIPT”) bioinformatics specialist based in Taiwan and its integration will provide Premaitha with increased access to Asia, the world’s fastest growing NIPT market, as well as opportunities for cross-selling.

Since the announcement of the acquisition, Yourgene has continued to win new customers for its in-house and lab-based NIPT solutions.  These include an Indonesian partner who will offer the first in-country NIPT service based on the Yourgene solution, and a laboratory in India which has purchased next-generation sequencing equipment ready to launch a Yourgene-based NIPT service in Q2.

Adam Reynolds, Chairman of Premaitha, commented: “We are delighted to have completed the acquisition of Yourgene. The combination of Yourgene and Premaitha will create a truly global platform from which we are able to offer safe, non-invasive prenatal screening tests to pregnant women. The board is also looking forward to working with the enlarged team, in particular to raise awareness of NIPT in Asia Pacific, which we believe will be a key growth market for Premaitha. The recent wins in Indonesia and India will also add sizeable target populations to the Company’s activities.”

For more information, please contact:

Premaitha Health PLC
Dr Stephen Little, Chief Executive Officer    
Barry Hextall, Chief Financial Officer    
This email address is being protected from spambots. You need JavaScript enabled to view it. 
Tel: +44 (0) 161 667 6865
    
Cairn Financial Advisers LLP (Nomad)
Liam Murray / Jo Turner    
Tel: +44 (0) 20 7213 0880
    
finnCap (Broker)    
Adrian Hargrave / Scott Mathieson (Corporate Finance)    
Tony Quirke (Corporate Broking)    
Tel: +44 (0) 20 7220 0500
    
Vigo Communications    
Ben Simons / Fiona Henson / Antonia Pollock    
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0) 20 7830 9700

About Premaitha
Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group’s primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market.

Premaitha’s IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample – which contains traces of fetal DNA – and estimates the risk of a fetus being affected with Down’s syndrome or other genetic conditions.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.

In December 2016, Premaitha announced the acquisition of Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha’s IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia – the world's fastest growing NIPT market – as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.

Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.

  • 13 June 2018 - Premaitha wins ‘Outstanding NIPS Solution Provider of the Year’ award +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha wins ‘Outstanding NIPS Solution Provider of the Year’ award

    Manchester, UK – 13 June 2018: Premaitha Health plc (AIM:NIPT), a leading international molecular diagnostics group, is proud to announce that it has today been presented with the “Outstanding Non-invasive Prenatal Screening (NIPS) Solution Provider of the Year” award at the China & America Precision Medicine Forum in Shanghai.  

    The award recognises Premaitha’s excellence as a leading

    Read More
  • 11 June 2018 - Partnership agreement for DNA sequencing technology development +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Partnership agreement for DNA sequencing technology development

    Manchester, UK – 11 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, announces that it has signed an agreement with Coastal Genomics, a biotechnology engineering firm based in Vancouver, Canada, to develop advanced technologies for clinical DNA sequencing tests.

    Coastal Genomics develops and markets automated solutions to address sample preparation needs across the medical diagnostics sector.

    Read More
  • 5 June 2018 - Premaitha signs NIPT partnership agreement in India +

    Premaitha Health plc
    (“Premaitha”, the “Company” or the “Group”)

    Premaitha signs NIPT partnership agreement in India

    Manchester, UK – 5 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces a 3-year agreement with one of the most advanced clinical laboratory groups in India (“Partner”), to provide a bespoke, high quality and scalable NIPT solution in the Indian market.

    Premaitha, through its Yourgene subsidiary (“Yourgene”),

    Read More
  • 15 May 2018 - Premaitha expands footprint with new laboratories in Kenya and India +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha expands footprint with new laboratories in Kenya and India

    Manchester, UK – 15 May 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces that it has further extended its customer base, adding two new laboratory hubs, one in Kenya – a new territory for Premaitha – and the other in India.

    In Kenya, the Group has signed

    Read More
  • 15 May 2018 - Year-end Trading Update and £2.5m Fundraising +

    Premaitha Health plc

    (“Premaitha”, the “Company” or the “Group”)

    Year-end Trading Update and £2.5m Fundraising

    Revenues doubled in the year ended 31 March 2018 & An additional £2.5m funds raised

    Manchester, UK – 15 May 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, provides a trading update for its financial year ended 31 March 2018; announces completion of a share subscription for £2.5m cash at a price of 4.5 pence per

    Read More
  • 29 March 2018 - Premaitha to attend key industry conferences in Asia Pacific +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha to attend key industry conferences in Asia Pacific

    Manchester, UK – 29 March 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, is pleased to announce it will be participating in key industry conferences in the Asia Pacific (“APAC”) region to raise awareness of its non-invasive prenatal testing (“NIPT”) solutions.

    Med Lab Asia Pacific

    Med Lab Asia Pacific will be

    Read More
  • 26 March 2018 - Update on UK patent infringement claim received in September 2017 +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Update on UK patent infringement claim received in September 2017

    Manchester, UK – 26 March 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular
    diagnostics group focused on non-invasive prenatal testing (“NIPT”), provides an update on the first
    stage of its UK defence against the new patent infringement claim, announced on 7 September 2017
    (“New UK Claim”).

    The New UK Claim from Illumina and Sequenom (the “Claimants”)

    Read More
  • 16 February 2018 - Premaitha secures market entry into Egypt +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha secures market entry into Egypt

    Manchester, UK – 16 February 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces that it has signed an exclusive agreement (the “Agreement”) with a new partner (the “Partner”) to offer the IONA ® test across Egypt. As a result of the Agreement, the Company is pleased to have secured its first

    Read More
  • 6 February 2018 - Premaitha raises awareness of the IONA® test at key conferences in the Middle East +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha raises awareness of the IONA ® test at key conferences in the Middle East

    Manchester, UK – 6 February 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, announces it will be participating in key conferences in the Middle East to further raise the profile of the IONA ® test across this region.  

    Medlab Dubai

    Medlab is one of

    Read More
  • 5 February 2018 - Premaitha’s IONA® test approved for sale in Brazil +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha’s IONA ® test approved for sale in Brazil

    Manchester, UK – 5 February 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, announces that the IONA ® test has been approved by Brazil’s regulatory authority, Agência Nacional de Vigilância Sanitária (“ANVISA”), for sale as an in vitro diagnostic (“IVD”) test.  

    In September 2017, Premaitha announced that the Company’s IONA

    Read More
  • 29 December 2017 - Half Year Results +

    Premaitha Health PLC
    (“Premaitha”, the “Company” or the “Group”)

    Half year results

    Manchester, UK – 29 December 2017: Premaitha Health PLC (AIM: NIPT), a leading molecular diagnostics group with a primary focus on the commercialisation of its non-invasive prenatal testing (“NIPT”) technology, announces half year results for the six months ended 30 September 2017.

    Financial highlights
    •    Revenues increased by 87% to £2.7m (H1 2016/17: £1.5m)
    •    Test volumes doubled to over 22,000 (H1 2016/17:

    Read More
  • 11 December 2017 - Premaitha secures four further laboratories in Europe +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Premaitha secures four further laboratories in Europe

    Manchester, UK – 11 December 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces further expansion of its European customer base, with four new laboratories added.

    The laboratories are situated across three EU countries. The Company’s European distributors secured three of the laboratories, with one laboratory having been contracted directly by

    Read More
  • 01 December 2017 - Premaitha CEO Wins Bionow Outstanding Contribution Award +

    Premaitha CEO Wins Bionow Outstanding Contribution Award

    Steve Little

    Manchester, UK – 1 December 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), is proud to announce that its CEO, Dr Stephen Little, last night received Bionow’s Outstanding Contribution award in recognition of his “significant contribution to the biomedical sector.”

    Bionow is an organisation which supports business growth, competitiveness and innovation within the biomedical and life science sectors

    Read More
  • 27 November 2017 - Middle East laboratory network expansion +

    Premaitha Health PLC
    (“Premaitha” or the “Company”)

    Middle East laboratory network expansion

    Manchester, UK – 27 November 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (NIPT), announces further expansion of its Middle Eastern customer base, with four new laboratories having been signed up in the region.

    Premaitha’s Middle Eastern distributors have secured four new laboratories seeking to offer the IONA ® test to their respective population

    Read More
  • 23 November 2017 - Premaitha signs new partner to offer NIPT solution in East Asia +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha signs new partner to offer NIPT solution in East Asia

    Manchester, UK – 23 November 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces that it has signed an agreement with a new laboratory partner (the “Partner”) to offer an NIPT screening solution in a new East Asian territory (the “Territory”) for Premaitha.  

    The Partner is

    Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
Pregnant lady sitting at table with Laptop

Investor Relations
Ben Simons / Fiona Henson
Vigo Communications
180 Piccadilly
London W1J 9HF
premaitha@vigocomms.com
T : +44 (0) 20 7830 9700

Two business people looking at computer screen